A Model of Growth Through Creative Destruction, Econometrica, vol.60, issue.2, pp.323-351, 1992. ,
The market for "lemons" : quality uncertainty and the market mechanism, Quarterly Journal of Economics, vol.84, issue.3, pp.488-500, 1970. ,
, Convergence of Probability Measures, 1999.
Wealth effects of food and drug administration (FDA) decisions, Managerial and Decision Economics, vol.15, issue.6, pp.589-599, 1994. ,
, Time Series and Forecasting, 1996.
Measuring security price performance, Journal of Financial Economics, vol.8, pp.205-258, 1980. ,
Using daily stock returns -the case of event studies, Journal of Financial Economics, vol.14, pp.3-31, 1985. ,
Les conflits juridiques liés à la propriété industrielle : le cas de l'industrie pharmaceutique et biotechnologique, Revue d'Economie Industrielle, vol.99, pp.87-105, 2002. ,
The value of interfirm coopertaion: an event study of new partnership announcements in the pharmaceutical industry, 2003. ,
Confidence Games: How does regulation constitute markets, 2009. ,
, Government and markets: Toward a new theory of regulation
Reputation, Information and Confidence: the Political Economy of Pharmaceutical Regulation, 2010. ,
Reputation and power: organizational image and pharmaceutical regulation at the FDA, 2010. ,
Regulatory Errors with Endogenous Agendas, American Journal of Political Science, vol.51, issue.4, pp.835-53, 2007. ,
Preventing Regulatory Capture: Special Interest Influence and how to limit, 2014. ,
Approval regulation and endogenous consumer confidence: Theory and analogies to licensing, safety, and financial regulation, Regulation & Governance, vol.4, issue.4, pp.383-407, 2010. ,
Tests of equality between sets of coefficients in two linear regressions, Econometrica, vol.28, issue.3, pp.591-605, 1960. ,
Stock price reaction to non-financial news in European technology companies, European Accounting Review, vol.20, issue.1, pp.81-111, 2010. ,
The Political (and Economic) Origins of Consumer Confidence, American Journal of Political Science, vol.48, issue.4, pp.633-649, 2004. ,
The adjustment of stock prices to new information, International Economic Review, vol.10, issue.1, pp.1-21, 1969. ,
Finance and Differential Accumulation in the global pharmaceutical industry, 2006. ,
Adopting Orphan Drugs -Two Dozen Years of Treating Rare Diseases, New England Journal of Medicine, vol.354, issue.5, pp.445-447, 2006. ,
, Acceptable Risks: Politics, Policy and Risky Technologies, 1997.
Drug approval decisions: a note on stock liquidity effect, Journal of Empirical Finance, vol.19, pp.640-652, 2012. ,
When public authorities foster and equip a protest movement. The invention of "rare diseases" in the United States and Europe, Revue Française de Science Politique, vol.61, pp.183-200, 2011. ,
Industries and globalization : the political causality of difference, 2008. ,
URL : https://hal.archives-ouvertes.fr/halshs-00371640
Accelerating Inflation, Technological Innovation, and the Decreasing Effectiveness of Banking Regulation, Journal of Finance, vol.36, pp.355-367, 1981. ,
The Determinants of Progressive Era Reform: The Pure Food and Drugs Act of 1906, in Corruption and Reform: Lessons from America's Economic History, pp.319-361, 2006. ,
Event studies in economics and finance, Journal of Economic Literature, vol.35, pp.13-39, 1997. ,
Heteroskedasticity-robust tests for structural change, Empirical Economics, vol.14, issue.2, pp.77-92, 1989. ,
Organizational Reputation and Jurisdictional Claims: The Case of the U.S. Food and Drug Administration, Governance, vol.23, issue.1, pp.133-159, 2010. ,
The Effect of Salient Reputational Threats on the Pace of FDA Enforcement, Governance, vol.26, issue.1, pp.31-61, 2013. ,
Organizational reputation, regulatory talk, and strategic silence, Journal of public administration research and theory, vol.23, issue.3, pp.581-608, 2013. ,
The Progress of Experiment: Science and Therapeutic Reform in the United States, 1900. ,
How industries change, Harvard Business Review, vol.82, issue.10, pp.86-94, 2004. ,
Orphan drugs: Relating price determination to disease prevalence, British Medical Journal, vol.341, issue.7770, 2010. ,
Promoting Agency Reputation through Public Advice: Advisory Committee Use in the FDA, Journal of Politics, vol.72, issue.3, pp.880-893, 2010. ,
Financialization and productive models in the pharmaceutical industry, Industrial and Corporate Change, vol.22, issue.4, pp.981-1030, 2013. ,
URL : https://hal.archives-ouvertes.fr/hal-00651727
Biotechnology stock prices before public announcements: evidence of insider trading, Journal of Investigative Medicine, vol.48, issue.2, pp.118-124, 2000. ,
Theories of Economic Regulation, The Bell Journal of Economics and Management Science, vol.5, issue.2, pp.335-358, 1971. ,
, fore and after public announcements related to oncology drugs, Journal of the National Cancer Institue, vol.103, issue.20, pp.1507-1515
Market response to FDA announcements, The Quarterly Review of Economics and Finance, vol.42, pp.586-597, 2006. ,
Linking product development outcomes to market valuation: the case of the U.S. pharmaceutical industry, Journal of Product Innovation Management, vol.21, issue.5, pp.297-308, 2004. ,
Market valuation of successful versus non-successful R&D efforts in the pharmaceutical industry, Journal of Business Finance & Accounting, vol.31, pp.1301-1325, 2004. ,
The Politics of Economic activity, 2016. ,
URL : https://hal.archives-ouvertes.fr/halshs-01378383
The theory of Economic Regulation, The Bell Journal of Economics and Management Science, vol.2, pp.3-21, 1971. ,
Overcoming adverse selection: How public intervention can restore market functioning, American Economic Review, vol.102, pp.29-59, 2012. ,
The Dynamic of Political-Bureaucratic Adaptation, American Journal of Political Science, vol.37, issue.2, pp.497-528, 1993. ,